title: Influence of estradiol on the secretion of oxytocin and prostaglandin F2 alpha during luteolysis in the ewe.
abstract: Twenty ewes of mixed breeds were randomly assigned in equal numbers to one of four groups in a 2 x 2 factorial design. The factors were x-irradiation to destroy ovarian follicles or sham irradiation and the administration of estradiol-containing or empty (placebo) implants. Surgery for irradiation was performed on Day 8 of the cycle. Blood samples were withdrawn from jugular catheters at 1.5-h intervals from Day 10 to Day 17. Luteolysis was not observed by Day 17 in 4 of 5 placebo-treated ewes after destruction of ovarian follicles. Luteolysis was observed in 4 of 5 ewes of the sham-irradiated, placebo-treated group and in all ewes that received estradiol whether or not ovarian follicles had been destroyed. The longest (p less than 0.07) interval between peaks of 13,14-dihydro-15-keto-prostaglandin F2 alpha (PGFM) was observed in the x-irradiated, placebo-treated group, whereas the administration of estradiol reduced (p less than 0.01) the interval between PGFM peaks. These findings indicate that a short interpulse interval in the secretion of prostaglandin F2 alpha (PGF2 alpha) is associated with luteolysis. It is possible that the reduced interpulse interval was either an effect of estradiol that caused luteolysis or a secondary event resulting from luteolysis. The administration of estradiol decreased (p less than 0.05) the number of episodes of oxytocin secretion during luteolysis and increased (p less than 0.01) the interval between episodes.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Veterinary Biosciences, University of Illinois College of Veterinary Medicine, Urbana 61801.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: P G
authors.initials: PG
authors.lastname: Weston
authors.forename: J E
authors.initials: JE
authors.lastname: Hixon
mesh_terms: D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism*; D004958:Estradiol / Q000097:blood / Q000494:pharmacology*; D004971:Estrus / Q000502:physiology; D005260:Female; D006080:Ovarian Follicle / Q000502:physiology / Q000528:radiation effects; D010052:Ovariectomy; D010121:Oxytocin / Q000378:metabolism*; D011374:Progesterone / Q000097:blood; D012756:Sheep / Q000502:physiology*
chemical_list: C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost